image by: HWN

HWN Suggests

Management of Helicobacter pylori in 2023: who should be tested, treated, and how

The conventional triple combination of a PPI, clarithromycin (Cl), and either amoxicillin (A) or metronidazole (Met) is no longer recommended because its success rates have decreased to less than 60%.

The new recommended first-line therapy is called concomitant or ClAMet (using the initials of clarithromycin (Cl), amoxicillin (A), and metronidazole (Met)) given for 14 days. Its efficacy is 80–85%.The best second-line therapy is bismuth-based quadruple therapy (PPI, bismuth, metronidazole, and tetracycline) given for 14 days. The higher dose of metronidazole 500 mg is the author’s preference as there is evidence that it can better overcome partial resistance to metronidazole. This…

read full article

Featured

 Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials https://www.mdpi.com/2076-2607/13/3/519 According to international guidelines for H. pylori management, classic bismuth quadruple therapy (cBQT) and concomitant therapy are recommended for empirical H. pylori eradication [8]. cBQT consists of an acid suppressant, bismuth, metronidazole, and tetracycline.

According to international guidelines for H. pylori management, classic bismuth quadruple therapy (cBQT) and concomitant therapy are recommended for empirical H. pylori eradication. cBQT consists of an acid suppressant, bismuth, metronidazole, and tetracycline.

 The Efficacy of Probiotics in the Management of Helicobacter Pylori: A Systematic Review

In conclusion, probiotics alone do not play a role in the eradication of Helicobacter pylori, but when combined with traditional treatment regimens, there is a slight increase in the eradication rates, which could be due to a reduction in the antibiotic-associated side effects, which leads to better patient adherence to the regimen.

 The twists and turns of fate

Helicobacter pylori has a reputation for causing ulcers and cancer. Hunting it to extinction, however, may be a mistake. MOST people feel a twinge of regret at reports that an animal or plant is becoming rare. Should they feel the same pangs for a bacterium? With Helicobacter pylori, so-called because of its twisty-turny shape, and famous for causing stomach ulcers and gastric cancer, the reaction would probably be “good riddance”. And H. pylori is, indeed, endangered in many parts of the planet. It is fast vanishing from the rich world, thanks to antibiotics and improved hygiene. Yet, as conservationists of larger organisms are quick to remind you, extinctions can have unexpected consequences. And that may prove to be the case with H. pylori.

Articles of Interest

From Antibiotic Resistance to Antibiotic Renaissance: A New Era in Helicobacter pylori Treatment

Treatment of H. pylori infection typically involves the use of antibiotics, and the most common regimens are triple therapy and quadruple therapy. Triple therapy typically involves a PPI and two antibiotics (clarithromycin and amoxicillin or metronidazole). Quadruple therapy typically consists of PPI, bismuth, metronidazole, and tetracycline.

Are probiotics useful in Helicobacter pylori eradication?

So far, mostly different types of Lactobacillus and S. boulardii were tested. The above-mentioned probiotics most probably decrease the bacterial load but don’t eradicate H. pylori completely in the gastric mucosa, if they are used as monotherapy. On the contrary, some probiotics when added to classical triple therapy may increase eradication rates. A reasonable amount of evidence exists that supplementation with S. boulardii is a useful concomitant therapy in the standard H. pylori eradication treatment protocol and most probably increases the eradication rate. L. reuteri is also a good candidate for adjunctive therapy, but more positive studies are needed. The effect of other probiotics strains is less well described.

Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics

In recent years, probiotics have become one of the most important tools for supporting intestinal health and immunity. Numerous in vitro studies, animal studies, and clinical observations have demonstrated that probiotics have the advantage of reducing side effects and increasing eradication rates in adjuvant anti-H. pylori therapy and are a valuable supplement to conventional therapy.

Current and Future Treatment of Helicobacter pylori Infections

Although successful antimicrobial therapy must be susceptibility-based, increasing antimicrobial resistance and general unavailability of susceptibility testing have required clinicians to generally rely on empiric regimens.

H. pylori, a true stomach “bug”: Who should doctors test and treat?

Treatment for H. pylori infection is challenging. It usually involves taking a combination of three or four medications multiple times a day for 14 days. And rising antibiotic resistance has made it increasingly difficult to cure the infection. The treatment is roughly 80% effective in getting rid of the infection, but the cure rate depends on picking the right combination of medications, taking them correctly, and finishing the full course of treatment.

Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents

Helicobacter pylori is considered one of the most prevalent human pathogenic microbes globally. It is the main cause of a number of gastrointestinal ailments, including peptic and duodenal ulcers, and gastric tumors with high mortality rates. Thus, eradication of H. pylori is necessary to prevent gastric cancer. Still, the rise in antibiotic resistance is the most important challenge for eradication strategies.

Non-pharmacological treatment of Helicobacter pylori

Compared with the use of antibiotic and PPI treatment, a preventive dietary approach can be very inexpensive in areas with poor health care systems. The food reviewed can be effective in preventing and/or reducing H. pylori infection due to their potent anti-inflammatory activity.

Novel Therapy Eradicates H pylori

Antimicrobial resistance to existing therapies has made Helicobacter pylori infection increasingly difficult to treat. In a phase 3 trial published in the Annals of Internal Medicine, a 3-drug combination of amoxicillin, omeprazole, and rifabutin in 1 capsule achieved high eradication rates of H pylori infection. The study’s 455 treatment-naive adults with confirmed H pylori infection were randomly assigned to receive the novel study drug or high-dose amoxicillin and omeprazole dual therapy for 14 days.

Preventing Helicobacter pylori Treatment Failure

The approach to the diagnosis and treatment of H. pylori is undergoing a paradigm shift because susceptibility testing has become readily available in the United States. This review discusses how to use susceptibility testing to its greatest advantage and how this information markedly changes the approach to therapy and reduces treatment failures. We also examine risk factors for treatment failure and propose methods to address barriers to eradication.

Role of Probiotics in the Management of Helicobacter pylori

Probiotics compete directly with H. pylori and help restore the gut microbial environment; these living microorganisms are comparatively more effective than the standard triple antibiotic regimen in the management of symptoms related to the pathogenic bacteria. The need for alternative therapy is better explained by the increasing rate of antibiotic resistance and the lowering of patient compliance to the standard treatment.

The Ideal Helicobacter pylori Treatment for the Present and the Future

The ideal concept for the present and future H. pylori eradication treatment involves “a simple, cost-effective strategy that fosters compliance without having a negative impact on the gut microbiota or contributing to future antimicrobial resistance.

What Works Best for Treating Helicobacter pylori Infection?

Helicobacter pylori infection in the stomach affects half of the population worldwide. Common treatments involve combining different types of medicine, some of which are antibiotics. However, some of these combinations are becoming less effective for treating Helicobacter pylori infection, due to antibiotic resistance. Vonoprazan and amoxicillin dual therapy treatment can be a good option, or even the best option, for some people with H. pylori infection, but it depends on their personal health situation and their health professional’s clinical decision-making.

Resources

CDC

Asymptomatic infections generally do not need to be treated. Determine treatment on an individual basis, and treat patients with active duodenal or gastric ulcers if they are infected. Standard treatment is bismuth quadruple therapy: proton pump inhibitor (PPI) or H2-blocker + bismuth + metronidazole + tetracycline. Clarithromycin triple therapy (PPI + clarithromycin + amoxicillin or metronidazole) is an option in regions where H. pylori clarithromycin resistance is known to be <15% and in patients with no previous history of macrolide exposure.